These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35613407)

  • 1. One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
    Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G
    J Ocul Pharmacol Ther; 2022 Jun; 38(5):354-358. PubMed ID: 35613407
    [No Abstract]   [Full Text] [Related]  

  • 2. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma.
    Inoue K; Shiokawa M; Kunimatsu-Sanuki S; Kang J; Uraki T; Tomita G; Ishida K
    Jpn J Ophthalmol; 2024 May; 68(3):206-210. PubMed ID: 38587788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
    Inoue K; Inoue J; Kunimatsu-Sanuki S; Nozaki N; Shimizu K; Ishida K; Tomita G
    Clin Ophthalmol; 2020; 14():2943-2949. PubMed ID: 33061280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
    J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
    Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
    Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
    Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
    Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
    Olander KW; Sato MA; Abrams MA; Jerkins GW; Lu F; Dinh P; Odani-Kawabata N; Chabi A; Shams NK
    J Glaucoma; 2021 Jun; 30(6):473-480. PubMed ID: 33813559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
    Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
    BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of 0.002% Omidenepag Isopropyl on Intraocular Pressure and the Cornea in Normal Tension Glaucoma.
    Lee SH; Lee WJ; Kim KW; Jeong JH; Park IK; Chun YS
    J Glaucoma; 2023 Apr; 32(4):245-251. PubMed ID: 36729067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
    Kuo HT; Yeh CY; Hsu AY; Ho JH; Lin CJ; Tsai YY
    J Ocul Pharmacol Ther; 2023 Dec; 39(10):705-715. PubMed ID: 37579061
    [No Abstract]   [Full Text] [Related]  

  • 13. Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.
    Fuwa M; Shimazaki A; Odani-Kawabata N; Kirihara T; Taniguchi T; Iwamura R; Yoneda K; Kato M; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2021 May; 37(4):223-229. PubMed ID: 33600237
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
    Nakano T; Yoshikawa K; Kimura T; Suzumura H; Nanno M; Noro T
    Jpn J Ophthalmol; 2011 Nov; 55(6):605-13. PubMed ID: 21874307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension.
    Shiratori N; Nishio Y; Takeda A; Sugimoto S; Takazawa K; Otsuka N; Ishida N; Shii D; Hori K; Nakamoto K
    Clin Ophthalmol; 2021; 15():3997-4003. PubMed ID: 34675468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma.
    Naito T; Okuma S; Nagayama M; Mizoue S; Ozaki M; Namiguchi K; Miyamoto K; Tanito M; Yoshikawa K
    Adv Ther; 2016 Mar; 33(3):435-46. PubMed ID: 26861847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study.
    Jin SW; Lee SM
    J Ocul Pharmacol Ther; 2018 Apr; 34(3):274-279. PubMed ID: 29297751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
    Aihara M; Lu F; Kawata H; Tanaka Y; Yamamura K; Odani-Kawabata N; Shams NK
    J Ocul Pharmacol Ther; 2019 Dec; 35(10):542-550. PubMed ID: 31674861
    [No Abstract]   [Full Text] [Related]  

  • 19. Intraocular pressure (IOP) reduction by latanoprost in Japanese normal tension glaucoma patients over a five-year period stratified by presenting IOP.
    Tsuda M; Ando A; Matsuyama K; Otsuji T; Fukui C; Maenishi N; Kuwahara A; Nishimura T; Jo N; Nambu H; Matsumura M
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):441-5. PubMed ID: 19857106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
    Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.